PLASMA T-PA AND PAI-1 ANTIGEN CONCENTRATIONS IN NON-INSULIN-DEPENDENT DIABETIC-PATIENTS - IMPLICATION FOR DIABETIC-RETINOPATHY

被引:5
作者
CHO, YW
YANG, DH
OH, DY
BAICK, SH
KIM, SK
KIM, SJ
HONG, SY
机构
[1] Department of Internal Medicine, Soonchunhyang University College of Medicine, Chunan, Chungnam
关键词
PLASMA T-PA; PAI-1; NIDDM; DIABETIC RETINOPATHY;
D O I
10.1016/0168-8227(94)90045-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Parameters of fibrinolysis, including basal plasma tissue type plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) antigen levels were studied in 49 non-insulin dependent diabetic patients (23 men, 26 women: ages 51.3 +/- 14.9 years) and 16 age matched non-diabetic subjects (9 men, 7 women ages 49.8 +/- 12.2 years) as a control group. Compared to a control group, the diabetic patients had a significantly higher mean plasma t-PA antigen (4.94 +/- 2.68 vs 3.20 +/- 2.30 ng/ml) and PAI-1 antigen (34.86 +/- 16.71 vs. 17.60 +/- 15.36 ng/ml) levels (P < 0.05). Significant univariate correlations were observed between t-PA and body mass index (BMI) (P=0.0009, r=0.7217), and PAI-1 were positively correlated with BMI and FBS (fasting blood sugar) in the total diabetic patients (P=0.0003, r=0.7217; P=0.0477, r=0.2858, respectively). In diabetic patients with proliferative diabetic retinopathy, both PAI-1 and t-PA antigen levels were significantly lower than those of diabetic patients with negative or background retinopathy (P= < 0.05). There were no significant differences of the plasma t-PA and PAI-1 levels between diabetic patients with micro- and macroproteinuria. This study conducted on non-insulin dependent diabetic patients suggests that they have significantly higher t-PA and PAI-1 antigen levels than do control subjects, and these findings appear to correlate negatively with proliferative retinopathy observed among the patients studied.
引用
收藏
页码:123 / 128
页数:6
相关论文
共 31 条
[1]  
ALESSI MC, 1988, THROMB HAEMOSTASIS, V60, P491
[2]  
ALMER LO, 1974, LANCET, V1, P1342
[3]  
ALMER LO, 1988, DIABETES METAB, V14, P519
[4]   DIABETIC-RETINOPATHY AND FIBRINOLYTIC SYSTEM [J].
ALMER, LO ;
PANDOLFI, M ;
NILSSON, IM .
DIABETES, 1975, 24 (06) :529-534
[5]  
AMIRAL J, 1984, CLIN CHEM, V30, P1512
[6]  
ASTRUP T, 1956, LANCET, V271, P565
[7]   TISSUE-TYPE PLASMINOGEN-ACTIVATOR ANTIGEN AND PLASMINOGEN-ACTIVATOR INHIBITOR IN DIABETES-MELLITUS [J].
AUWERX, J ;
BOUILLON, R ;
COLLEN, D ;
GEBOERS, J .
ARTERIOSCLEROSIS, 1988, 8 (01) :68-72
[8]   FIBRINOLYTIC RESPONSE TO MODERATE EXERCISE IN YOUNG MALE DIABETICS AND NON-DIABETICS [J].
CASH, JD ;
MCGILL, RC .
JOURNAL OF CLINICAL PATHOLOGY, 1969, 22 (01) :32-+
[9]   EUGLOBULIN FIBRINOLYTIC-ACTIVITY IN NIDDM PATIENTS [J].
CHO, YW ;
OH, DY ;
KIM, SJ ;
HONG, SY ;
LEE, HC ;
HUH, KB .
DIABETES RESEARCH AND CLINICAL PRACTICE, 1991, 13 (03) :139-146
[10]  
COLLEN D, 1983, THROMB HAEMOSTASIS, V50, P678